theobromine has been researched along with Parkinsonian Disorders in 4 studies
Theobromine: 3,7-Dimethylxanthine. The principle alkaloid in Theobroma cacao (the cacao bean) and other plants. A xanthine alkaloid that is used as a bronchodilator and as a vasodilator. It has a weaker diuretic activity than THEOPHYLLINE and is also a less powerful stimulant of smooth muscle. It has practically no stimulant effect on the central nervous system. It was formerly used as a diuretic and in the treatment of angina pectoris and hypertension. (From Martindale, The Extra Pharmacopoeia, 30th ed, pp1318-9)
theobromine : A dimethylxanthine having the two methyl groups located at positions 3 and 7. A purine alkaloid derived from the cacao plant, it is found in chocolate, as well as in a number of other foods, and is a vasodilator, diuretic and heart stimulator.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| EHLERS, G | 1 |
| MUSTARD, DM | 1 |
| Alfinito, PD | 1 |
| Wang, SP | 1 |
| Manzino, L | 1 |
| Rijhsinghani, S | 1 |
| Zeevalk, GD | 1 |
| Sonsalla, PK | 2 |
| Chen, JF | 1 |
| Xu, K | 1 |
| Petzer, JP | 1 |
| Staal, R | 1 |
| Xu, YH | 1 |
| Beilstein, M | 1 |
| Castagnoli, K | 1 |
| Castagnoli, N | 1 |
| Schwarzschild, MA | 1 |
4 other studies available for theobromine and Parkinsonian Disorders
| Article | Year |
|---|---|
[On the applicability of cosaldon in the treatment of cerebral sclerotic parkinsonism].
Topics: Drug Combinations; Niacin; Nicotinic Acids; Parkinson Disease; Parkinsonian Disorders; Theobromine; | 1959 |
TREATMENT OF PARKINSONISM IN ELDERLY PATIENTS WITH COSALDON.
Topics: Cerebrovascular Circulation; Drug Combinations; Drug Therapy; Geriatrics; Intracranial Arteriosclero | 1964 |
Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively.
Topics: Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Corpus Str | 2003 |
Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Caffeine; Cat | 2001 |